Clinical Trial Goal
To find out if the combination of mogamulizumab and intensive chemo is safe and works well to treat T-NHL
You may be able to join this trial if you:
- Are 18 years old or older
- Have T-NHL. Some examples include:
- Adult T-cell lymphoma leukemia
- Anaplastic large-cell lymphoma
- Angioimmunoblastic T-cell lymphoma
- Cutaneous T-cell lymphoma
- Enteropathy-associated T-cell lymphoma
- Gamma delta T-cell lymphomas
- Hepatosplenic T-cell lymphomas
- Peripheral T-cell lymphoma not otherwise specified (PTCL nos)
- Sezary syndrome
- Subcutaneous panniculitis-like T-cell lymphoma
- T-prolymphocytic leukemia
- Transformed mycosis fungoides
- Do not have lymphoma in your brain or spinal cord
- Have not had allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 2 years
- Do not have graft-versus-host-disease (GVHD)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
CHOEP is an intensive chemo treatment that includes cyclophosphamide, etoposide, hydroxydaunorubicin, prednisone and vincristine
DA-EPOCH is an intensive chemo treatment that includes dose-adjusted cyclophosphamide, doxorubicin, etoposide, prednisone and vincristine.
Cyclophosphamide, doxorubicin, hydroxydaunorubicin, etoposide and vincristine are chemotherapy (chemo) drugs that block the growth of cancer cells.
Mogamulizumab is a monoclonal antibody that targets CCR4 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
DA-EPOCH is an intensive chemo treatment that includes dose-adjusted cyclophosphamide, doxorubicin, etoposide, prednisone and vincristine.
Cyclophosphamide, doxorubicin, hydroxydaunorubicin, etoposide and vincristine are chemotherapy (chemo) drugs that block the growth of cancer cells.
Mogamulizumab is a monoclonal antibody that targets CCR4 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- CHOEP or DA-EPOCH – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Mogamulizumab – Given as IV infusions up to 1 time each week
You may continue treatment for 4.5 months. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat T-NHL is new and unproven.
Contacts
Carole Ramm, (203) 785-4095, carole.ramm@yale.edu
Stephanie Ladd, 954-895-0576, stephanie.ladd@yale.edu
Locations
Yale Cancer Center, Clinical Trials OfficeRECRUITING
New Haven, Connecticut
Daniel Moncayo, 203-500-0834, daniel.moncayo@yale.edu
Icahn School of Medicine at Mount SinaiRECRUITING
New York, New York
Martin van Voorthuysen, 646-745-6092, martine.vanvoorthuysen@mssm.edu
Sponsors
collaborator: Kyowa Kirin, Inc., lead: Yale University
